Systemic Anti-Cancer Therapy Regimen Library New Zealand Formulary

Head and Neck Regimens

Nasopharyngeal Regimens

Published Sort regimens by
HN NPC Locally advanced - cARBOplatin chemoradiation followed by cARBOplatin and fluorouracil Id: 59481000210102 Published date: Version: 2.0.0
59481000210102
2.0.0
19/02/2025
HN NPC Locally advanced - cISplatin [Q1W] chemoradiation Id: 59331000210107 Published date: Version: 3.0.0
59331000210107
3.0.0
07/05/2026
HN NPC Locally advanced - cISplatin [Q3W] chemoradiation followed by cISplatin and fluorouracil Id: 59441000210109 Published date: Version: 2.0.0
59441000210109
2.0.0
07/05/2026
HN NPC Locally advanced - gemcitabine and cISplatin induction followed by cISplatin chemoradiation Id: 497001000210108 Published date: Version: 1.0.0
Components ▾
Part 1: gemcitabine and cISplatin induction Id: 497011000210105 Published date: Version: 0.0.5
Part 2: cISplatin [Q1W] chemoradiation Id: 497021000210100 Published date: Version: 0.0.4
OR Part 2: cISplatin [Q3W] chemoradiation Id: 497031000210103 Published date: Version: 0.0.2
497001000210108
1.0.0
10/03/2025
HN NPC Metastatic - gemcitabine [Q4W] Id: 60231000210101 Published date: Version: 1.0.0
60231000210101
1.0.0
19/12/2022
HN NPC Metastatic - gemcitabine and cARBOplatin Id: 59381000210106 Published date: Version: 1.0.0
59381000210106
1.0.0
02/06/2022
HN NPC Metastatic - gemcitabine and cISplatin Id: 59361000210103 Published date: Version: 2.0.0
59361000210103
2.0.0
07/05/2026
Superseded Regimens Sort regimens by
HN NPC Locally advanced - gemcitabine and cISplatin followed by cISplatin chemoradiation Id: 59471000210104 Published date: Version: 1.0.2
59471000210104
1.0.2
29/03/2026

Salivary gland Regimens

Published Sort regimens by
HN SAL Metastatic - CAP [CYCLOPHOSPHamide, DOXOrubicin and cISplatin] Id: 59431000210101 Published date: Version: 2.0.0
59431000210101
2.0.0
07/05/2026
HN SAL Metastatic - cISplatin and vinORELBine [IV] Id: 59461000210105 Published date: Version: 2.0.0
59461000210105
2.0.0
07/05/2026
HN SAL Metastatic - cISplatin and vinORELBine [oral] Id: 506571000210103 Published date: Version: 1.0.0
506571000210103
1.0.0
23/01/2026

Squamous cell Regimens

Published Sort regimens by
HN SQCC Locally advanced - cISplatin [Q1W] post-operative chemoradiation Id: 59241000210105 Published date: Version: 3.0.0
59241000210105
3.0.0
19/02/2025
HN SQCC Locally advanced - cISplatin [Q3W] post-operative chemoradiation Id: 59501000210105 Published date: Version: 2.0.0
59501000210105
2.0.0
07/05/2026
HN SQCC Locally advanced/Definitive - cARBOplatin and fluorouracil chemoradiation Id: 59231000210102 Published date: Version: 3.0.0
59231000210102
3.0.0
08/05/2026
HN SQCC Locally advanced/Definitive - cARBOplatin [Q1W] chemoradiation Id: 506581000210101 Published date: Version: 1.0.0
506581000210101
1.0.0
23/01/2026
HN SQCC Locally advanced/Definitive - CETUximab chemoradiation Id: 60101000210103 Published date: Version: 2.0.0
60101000210103
2.0.0
13/03/2025
HN SQCC Locally advanced/Definitive - cISplatin [Q1W] chemoradiation Id: 59321000210105 Published date: Version: 3.0.0
59321000210105
3.0.0
07/05/2026
HN SQCC Locally advanced/Definitive - cISplatin [Q3W] chemoradiation Id: 59451000210107 Published date: Version: 2.0.0
59451000210107
2.0.0
07/05/2026
HN SQCC Locally advanced/Definitive - DOCEtaxel [Q1W] chemoradiation Id: 506591000210104 Published date: Version: 1.0.0
506591000210104
1.0.0
23/01/2026
HN SQCC Locally advanced - pembrolizumab induction followed by cISplatin and pembrolizumab chemoradiation followed by pembrolizumab Id: 588361000210103 Published date: Version: 1.0.0
Components ▾
pembrolizumab Q3W induction Id: 588371000210109 Published date: Version: 0.0.3
EITHER: cISplatin Q1W and pembrolizumab Q3W chemoradiation Id: 588381000210106 Published date: Version: 0.0.7
OR: cISplatin Q3W and pembrolizumab Q3W chemoradiation Id: 588391000210108 Published date: Version: 0.0.8
pembrolizumab Q3W continuation Id: 588521000210102 Published date: Version: 0.0.4
588361000210103
1.0.0
26/08/2026
HN SQCC Locally advanced - TPF [DOCEtaxel, ciSplatin and fluorouracil] followed by cARBOplatin chemoradiation Id: 60111000210101 Published date: Version: 2.0.0
60111000210101
2.0.0
07/05/2026
HN SQCC Metastatic - cARBOplatin and fluorouracil [Q3W] Id: 59491000210100 Published date: Version: 1.0.0
59491000210100
1.0.0
02/06/2022
HN SQCC Metastatic - cARBOplatin and PACLItaxel Id: 59351000210101 Published date: Version: 3.0.0
59351000210101
3.0.0
06/09/2023
HN SQCC Metastatic - cARBOplatin, fluorouracil and pembrolizumab Id: 59371000210109 Published date: Version: 1.0.0
59371000210109
1.0.0
02/06/2022
HN SQCC Metastatic - cARBOplatin, PACLItaxel and pembrolizumab Id: 506601000210109 Published date: Version: 1.0.0
506601000210109
1.0.0
23/01/2026
HN SQCC Metastatic - cISplatin and fluorouracil Id: 59341000210104 Published date: Version: 2.0.0
59341000210104
2.0.0
07/05/2026
HN SQCC Metastatic - cISplatin, fluorouracil and pembrolizumab Id: 59421000210103 Published date: Version: 2.0.0
59421000210103
2.0.0
07/05/2026
HN SQCC Metastatic - metHOTREXATe Id: 60121000210106 Published date: Version: 1.0.0
60121000210106
1.0.0
07/11/2022
HN SQCC Metastatic - nivolumab [weight-based dosing] Id: 59221000210104 Published date: Version: 1.0.0
59221000210104
1.0.0
05/05/2022
HN SQCC Metastatic - nivolumab Q2W [flat dosing] Id: 59411000210108 Published date: Version: 1.0.0
59411000210108
1.0.0
02/06/2022
HN SQCC Metastatic - nivolumab Q4W [flat dosing] Id: 59251000210108 Published date: Version: 1.0.0
59251000210108
1.0.0
05/05/2022
HN SQCC Metastatic - PACLItaxel Q1W Id: 59401000210106 Published date: Version: 1.0.0
59401000210106
1.0.0
02/06/2022
HN SQCC Metastatic - pembrolizumab Q3W [flat dosing] Id: 59201000210107 Published date: Version: 1.0.0
59201000210107
1.0.0
05/05/2022
HN SQCC Metastatic - pembrolizumab Q3W [weight-based dosing] Id: 59391000210108 Published date: Version: 1.0.0
59391000210108
1.0.0
02/06/2022
HN SQCC Metastatic - pembrolizumab Q6W [flat dosing] Id: 59211000210109 Published date: Version: 1.0.0
59211000210109
1.0.0
05/05/2022

Thyroid Regimens

Published Sort regimens by
HN THY Locally advanced/Metastatic - daBRAFEnib and tRAMEtinib Id: 506611000210106 Published date: Version: 1.0.0
506611000210106
1.0.0
23/01/2026
HN THY Metastatic - leNVAtinib Id: 59511000210107 Published date: Version: 1.0.0
59511000210107
1.0.0
03/06/2022